切除的胰腺腺癌患者术中放疗的早期经验。
Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma.
作者信息
Messick Craig, Hardacre Jeffrey M, McGee Michael F, Siegel Christopher T, Stellato Thomas A, Sanabria Juan R, Kinsella Timothy J, Schulak James A
机构信息
Department of Surgery, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH 44106-5047, USA.
出版信息
Am J Surg. 2008 Mar;195(3):308-11; discussion 312. doi: 10.1016/j.amjsurg.2007.12.024.
BACKGROUND
The use of intraoperative radiotherapy (IORT) in patients with resected pancreatic adenocarcinoma has not been clearly defined.
METHODS
The medical records of our first 22 patients receiving IORT for resected pancreatic adenocarcinoma (2001 to 2006) were reviewed and compared with the records of 27 consecutive patients not receiving IORT for resected pancreatic adenocarcinoma (2004 to 2006).
RESULTS
There were no 30-day mortalities in either group, and complication rates were similar. Local recurrence occurred in 18% in the IORT group (median 14 months) and 12% in the no-IORT group (median 7 months). Distant recurrence occurred in 47% in the IORT group (median 11 months) and 32% in the no-IORT group (median 6.5 months). Median overall, stage-specific, and location-specific survival did not differ between the groups.
CONCLUSIONS
Although limited in size and follow-up, our experience showed that complications, recurrence, and survival were not affected by IORT, but time to recurrence may be longer with IORT.
背景
术中放疗（IORT）在接受胰腺腺癌切除术患者中的应用尚未明确界定。
方法
回顾了我们最初22例接受IORT治疗的胰腺腺癌切除术患者（2001年至2006年）的病历，并与27例连续未接受IORT治疗的胰腺腺癌切除术患者（2004年至2006年）的病历进行比较。
结果
两组均无30天死亡率，并发症发生率相似。IORT组局部复发率为18%（中位时间14个月），非IORT组为12%（中位时间7个月）。IORT组远处复发率为47%（中位时间11个月），非IORT组为32%（中位时间6.5个月）。两组的总体、分期特异性和部位特异性生存中位数无差异。
结论
尽管样本量和随访时间有限，但我们的经验表明，IORT不影响并发症、复发和生存，但IORT组的复发时间可能更长。
Zotero 插件